ADVERTISEMENT
Biosimilars
As Fresenius delivered its third-quarter results, the firm’s Fresenius Kabi division celebrated sales growth of two-thirds in its Biopharma biosimilars segment amid several solid increases seen in Q3.
As the pharmaceutical industry readies itself to navigate the complexities of 2025, US pricing trends reveal a landscape shaped by regulatory and legislative changes, innovative pricing models, and the ongoing impact of inflation.
As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.
Fresenius Kabi-controlled mAbxience has struck a deal with Servier’s Egis Pharmaceutical to commercialize two biosimilar candidates in multiple central and eastern European markets.
Running from 11-14 November, the fifth annual Global Biosimilars Week awareness campaign has been launched by the IGBA, with the international off-patent association this year focusing on advancing access.
After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.
Meitheal has announced a licensing agreement with parent company Hong Kong King-Friend to add another three biosimilars to its pipeline for the US market.
After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.
Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.
Alvotech and Advanz have celebrated a worldwide first with the European Medicines Agency’s acceptance of an application for their partnered golimumab biosimilar rival to Simponi.